Erythropoiesis-Stimulating Agents / Steve Elliot. - Chapter 4; p. 55-74
Published in:
Hematopoietic Growth Factors in Oncology. - Boston, MA, Springer. - (Cancer Treatment and Research book series (CTAR); volume 157)
- DOI: 10.1007/978-1-4419-7073-2_4
- Print ISBN 978-1-4419-7072-5
- Online ISBN 978-1-4419-7073-2
Abstract
Erythropoiesis is the process whereby erythroid progenitor cells differentiate and divide, resulting in increased numbers of red blood cells (RBCs). RBCs contain hemoglobin, the main oxygen carrying component in blood. The large number of RBCs found in blood is required to support the prodigious consumption of oxygen by tissues as they undergo oxygen-dependent processes. Erythropoietin is a hormone that when it binds and activates Epo receptors resident on the surface of cells results in stimulation of erythropoiesis. Successful cloning of the EPO gene allowed for the first time production of recombinant human erythropoietin and other erythropoiesis stimulating agents (ESAs), which are used to treat anemia in patients. In this chapter, the control of Epo levels and erythropoiesis, the various forms of ESAs used commercially, and their physical and biological properties are discussed.
